Header Logo

Connection

RACHELLE DOODY to Treatment Outcome

Back to Details
This is a "connection" page, showing publications RACHELLE DOODY has written about Treatment Outcome.
RACHELLE DOODY
Connection Strength
0.850
Treatment Outcome
  1. Long-term safety of gantenerumab in participants with Alzheimer's disease: A phase III, open-label extension study (SCarlet RoAD). J Alzheimers Dis. 2025 Jan; 103(2):528-541.
    View in: PubMed
    Score: 0.079
  2. Long-Term Safety of Gantenerumab in Participants with Alzheimer's Disease: A Phase III, Double-Blind, and Open-Label Extension Study (Marguerite RoAD). J Alzheimers Dis. 2024; 101(1):353-367.
    View in: PubMed
    Score: 0.074
  3. Evaluating the Safety and Efficacy of Crenezumab vs Placebo in Adults With Early Alzheimer Disease: Two Phase 3 Randomized Placebo-Controlled Trials. JAMA Neurol. 2022 11 01; 79(11):1113-1121.
    View in: PubMed
    Score: 0.069
  4. Editorial: Consequences of the FDA Decision on Aducanumab for Patient Care and Research. J Prev Alzheimers Dis. 2021; 8(4):393-395.
    View in: PubMed
    Score: 0.060
  5. Gantenerumab reduces amyloid-? plaques in patients with prodromal to moderate Alzheimer's disease: a PET substudy interim analysis. Alzheimers Res Ther. 2019 12 12; 11(1):101.
    View in: PubMed
    Score: 0.056
  6. Efficacy and Safety of Donepezil in Chinese Patients with Severe Alzheimer's Disease: A Randomized Controlled Trial. J Alzheimers Dis. 2017; 56(4):1495-1504.
    View in: PubMed
    Score: 0.046
  7. A hidden Markov model approach to analyze longitudinal ternary outcomes when some observed states are possibly misclassified. Stat Med. 2016 Apr 30; 35(9):1549-57.
    View in: PubMed
    Score: 0.043
  8. Efficacy and safety of donepezil 23 mg versus donepezil 10 mg for moderate-to-severe Alzheimer's disease: a subgroup analysis in patients already taking or not taking concomitant memantine. Dement Geriatr Cogn Disord. 2012; 33(2-3):164-73.
    View in: PubMed
    Score: 0.033
  9. Validity, significance, strengths, limitations, and evidentiary value of real-world clinical data for combination therapy in Alzheimer's disease: comparison of efficacy and effectiveness studies. Neurodegener Dis. 2012; 10(1-4):170-4.
    View in: PubMed
    Score: 0.033
  10. Evolving early (pre-dementia) Alzheimer's disease trials: suit the outcomes to the population and study design. J Nutr Health Aging. 2010 Apr; 14(4):299-302.
    View in: PubMed
    Score: 0.029
  11. Safety and tolerability of donepezil in mild cognitive impairment: open-label extension study. Am J Alzheimers Dis Other Demen. 2010 Mar; 25(2):155-9.
    View in: PubMed
    Score: 0.028
  12. Donepezil treatment of patients with MCI: a 48-week randomized, placebo-controlled trial. Neurology. 2009 May 05; 72(18):1555-61.
    View in: PubMed
    Score: 0.026
  13. Effect of dimebon on cognition, activities of daily living, behaviour, and global function in patients with mild-to-moderate Alzheimer's disease: a randomised, double-blind, placebo-controlled study. Lancet. 2008 Jul 19; 372(9634):207-15.
    View in: PubMed
    Score: 0.025
  14. Safety and tolerability of donepezil at doses up to 20 mg/day: results from a pilot study in patients with Alzheimer's disease. Drugs Aging. 2008; 25(2):163-74.
    View in: PubMed
    Score: 0.025
  15. Refining treatment guidelines in Alzheimer's disease. Geriatrics. 2005 Jun; Suppl:14-20.
    View in: PubMed
    Score: 0.020
  16. Sustained effect of prasinezumab on Parkinson's disease motor progression in the open-label extension of the PASADENA trial. Nat Med. 2024 Dec; 30(12):3669-3675.
    View in: PubMed
    Score: 0.020
  17. Specific functional effects of memantine treatment in patients with moderate to severe Alzheimer's disease. Dement Geriatr Cogn Disord. 2004; 18(2):227-32.
    View in: PubMed
    Score: 0.019
  18. Current treatments for Alzheimer's disease: cholinesterase inhibitors. J Clin Psychiatry. 2003; 64 Suppl 9:11-7.
    View in: PubMed
    Score: 0.017
  19. Trial of Prasinezumab in Early-Stage Parkinson's Disease. N Engl J Med. 2022 08 04; 387(5):421-432.
    View in: PubMed
    Score: 0.017
  20. Chronic donepezil treatment is associated with slowed cognitive decline in Alzheimer's disease. Dement Geriatr Cogn Disord. 2001 Jul-Aug; 12(4):295-300.
    View in: PubMed
    Score: 0.016
  21. Open-label, multicenter, phase 3 extension study of the safety and efficacy of donepezil in patients with Alzheimer disease. Arch Neurol. 2001 Mar; 58(3):427-33.
    View in: PubMed
    Score: 0.015
  22. Therapeutic standards in Alzheimer disease. Alzheimer Dis Assoc Disord. 1999 Nov; 13 Suppl 2:S20-6.
    View in: PubMed
    Score: 0.014
  23. PRISM II: an open-label study to assess effectiveness of dextromethorphan/quinidine for pseudobulbar affect in patients with dementia, stroke or traumatic brain injury. BMC Neurol. 2016 Jun 09; 16:89.
    View in: PubMed
    Score: 0.011
  24. Davunetide in patients with progressive supranuclear palsy: a randomised, double-blind, placebo-controlled phase 2/3 trial. Lancet Neurol. 2014 Jul; 13(7):676-85.
    View in: PubMed
    Score: 0.010
  25. Evaluating the cognitive effects of donepezil 23 mg/d in moderate and severe Alzheimer's disease: analysis of effects of baseline features on treatment response. BMC Geriatr. 2013 Jun 06; 13:56.
    View in: PubMed
    Score: 0.009
  26. Long-term treatment with lithium alleviates memory deficits and reduces amyloid-? production in an aged Alzheimer's disease transgenic mouse model. J Alzheimers Dis. 2011; 24(4):739-49.
    View in: PubMed
    Score: 0.008
  27. Report of the task force on designing clinical trials in early (predementia) AD. Neurology. 2011 Jan 18; 76(3):280-6.
    View in: PubMed
    Score: 0.008
  28. A phase 2 multiple ascending dose trial of bapineuzumab in mild to moderate Alzheimer disease. Neurology. 2009 Dec 15; 73(24):2061-70.
    View in: PubMed
    Score: 0.007
  29. Donepezil preserves cognition and global function in patients with severe Alzheimer disease. Neurology. 2007 Jul 31; 69(5):459-69.
    View in: PubMed
    Score: 0.006
  30. Longitudinal MRI findings from the vitamin E and donepezil treatment study for MCI. Neurobiol Aging. 2008 Sep; 29(9):1285-95.
    View in: PubMed
    Score: 0.006
  31. Realistic expectations for treatment success in Alzheimer's disease. J Nutr Health Aging. 2006 Sep-Oct; 10(5):417-29.
    View in: PubMed
    Score: 0.006
  32. A 24-week open-label extension study of memantine in moderate to severe Alzheimer disease. Arch Neurol. 2006 Jan; 63(1):49-54.
    View in: PubMed
    Score: 0.005
  33. Donepezil in vascular dementia: a randomized, placebo-controlled study. Neurology. 2003 Aug 26; 61(4):479-86.
    View in: PubMed
    Score: 0.005
  34. Estrogen replacement therapy for treatment of mild to moderate Alzheimer disease: a randomized controlled trial. Alzheimer's Disease Cooperative Study. JAMA. 2000 Feb 23; 283(8):1007-15.
    View in: PubMed
    Score: 0.004
  35. Donepezil improves cognition and global function in Alzheimer disease: a 15-week, double-blind, placebo-controlled study. Donepezil Study Group. Arch Intern Med. 1998 May 11; 158(9):1021-31.
    View in: PubMed
    Score: 0.003
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.